 In that study, 106 weeks of adjunctive treatment of chronic heart failure patients with 3 times 100 milligrams of a daily ubiquinone Coenzyme Q10 supplement in addition to conventional heart failure medicine was associated with significant reductions in major adverse cardiovascular events, cardiovascular mortality, all-cause mortality, and hospitalizations as compared to placebo.In the European segment of the Q-Symbio Study, the active Coenzyme Q10 treatment also increased the patients’ left ventricular ejection fraction significantly.During a period of high exertion in 1998, Judy had a major heart attack.